Stay updated on Nivolumab and Ipilimumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab and Ipilimumab in Melanoma Clinical Trial page.

Latest updates to the Nivolumab and Ipilimumab in Melanoma Clinical Trial page
- Check6 days agoChange DetectedRemoved the term 'Melanoma' and the 'MedlinePlus Genetics' related topics section from the study details page. This changes the visible scope of the page and its linked resources.SummaryDifference0.1%

- Check13 days agoChange DetectedMelanoma was added as a related topic/MeSH term. The page revision updated to v3.4.2 and the older v3.4.1 revision notice and government funding notice were removed.SummaryDifference0.3%

- Check21 days agoChange DetectedA government funding notice and a new UI revision tag (Revision: v3.4.1) were added, while older revision text (v3.4.0) and some taxonomy labels (Melanoma, MedlinePlus Genetics, related topics) were removed. These updates are administrative and do not alter the study content, eligibility, enrollment, or location details.SummaryDifference0.3%

- Check28 days agoChange DetectedMinor editorial/UI updates were implemented: a 'Show glossary' option was added, capitalization differences in 'No FEAR Act Data' were standardized, and the QC-related label 'Last Update Submitted that Met QC Criteria' along with the page revision indicator were updated to v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check42 days agoChange DetectedSite revision updated from v3.3.3 to v3.3.4; no changes to study details, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check49 days agoChange DetectedMelanoma is added as a related disease tag and MedlinePlus Genetics is listed as a related topic. These are supplemental navigation/resources and do not modify the study data or eligibility criteria.SummaryDifference0.1%

Stay in the know with updates to Nivolumab and Ipilimumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab and Ipilimumab in Melanoma Clinical Trial page.